What Will Decide Merck Stock Over The Next Six Months? Trefis Team Fri, November 13, 2026 at 11:35 AM EST 4 min read MRK -0.50% ^GSPC -0.96% PFE -0.35% JNJ +0.93% LLY +0.90% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
For questions about this article or underlying research, email help@trefis.com.
Merck (MRK) stock returned 66.3% over the twelve months to November 12, 2026, against 12.2% for the S&P 500. Yet management has already said it expects only moderate sales growth in 2027, a year it calls another year of investment in its pipeline and new launches. Below are the events most likely to move Merck stock over the next six months.
Generic competition for Bridion, Adempas and the Januvia family, with a government-set price for Janumet
Underway (Bridion); Janumet price from January 1, 2027
Fiscal Q4 2026 results, against the full-year 2026 revenue guide
Keytruda growth moderating, and its expected selection for government price setting
Underlying operating expenses rising at a mid- to high-single-digit rate
Generic Rivals For Three Older Drugs
Merck's older drugs Bridion, Adempas and the Januvia family will lose sales to generic competition in 2027. Management puts that hit at more than $2 billion for the year. Generic copies of Bridion have already entered the market, while the Januvia family faces a government-set price for Janumet that takes effect on January 1, 2027.
Those losses compare with $67.4 billion of revenue over the twelve months to September 2026. Management expects strong contributions from new product launches and the animal health business, partly offset by those losses, and that is why it sees only moderate sales growth in 2027. Management also expects underlying operating expenses to rise at a mid- to high-single-digit rate in 2027 as it invests behind its pipeline and launches. The thing to watch is what the new launches add against those losses, which each quarterly report will show.
Keytruda's Slowing Growth And Price Setting
Merck's cancer drug Keytruda faces two changes. Management sees its growth moderating now, and the company expects the therapy to be selected during 2027 for government price setting. The set price would take effect on January 1, 2029. The Keytruda family sold $8.6 billion in fiscal Q3 2026, against total company revenue of $18.1 billion.
Excluding currency moves, those Keytruda sales grew 6% in the quarter. Management said growth is moderating because the drug has reached peak use in several cancers. Keytruda family sales growth, reported every quarter, is the measure to watch, along with whether the drug is named for price setting during 2027.
Merck's Fourth-Quarter Report In February 2027
Merck is expected to report its fiscal Q4 2026 results in February 2027. On October 29, 2026, management narrowed its full-year 2026 revenue guide to $66.8 billion to $67.3 billion and raised the midpoint. That range sits below the $67.4 billion of sales in the four quarters to September 2026, which implies fourth-quarter sales under the $16.4 billion of a year earlier.
The fourth quarter also gives back the extra Keytruda purchases that lifted the third quarter, an impact management put at $200 million. The February report will show whether 2026 sales land inside the narrowed range once that timing reverses. Keytruda family sales for the fourth quarter are the number to watch in that report.
Can You Hold Merck Through These Dates?
Over the past year, Merck stock saw its worst fall when it dropped 11.9% over 46 trading sessions from February 24 to April 30, 2026. Holding through the next six months means being ready for a fall of that size again.
If a drop of that size in your Merck holding would make you sell, the position is larger than one you could hold through a repeat.
Is One Stock Too Big A Part Of Your Portfolio?
A fall in any one stock hurts most when that position carries too much weight. Bring that question to a free 30-minute call with our partner advisory firm, by phone or video, with no obligation.
Spot an error or want more like this? Tell us in 10 seconds.
